These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27155683)

  • 41. Diagnosis and treatment of Helicobacter pylori infection.
    Bytzer P; Dahlerup JF; Eriksen JR; Jarbøl DE; Rosenstock S; Wildt S;
    Dan Med Bull; 2011 Apr; 58(4):C4271. PubMed ID: 21466771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drugs for GERD and peptic ulcer disease.
    Med Lett Drugs Ther; 2018 Jan; 60(1538):9-16. PubMed ID: 29309399
    [No Abstract]   [Full Text] [Related]  

  • 43. [Current therapy of Helicobacter pylori-induced chronic gastritis and/or peptic ulcer].
    Hentschel E
    Wien Klin Wochenschr; 1994; 106(17):543-6. PubMed ID: 7975668
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of clarithromycin in eradicating Helicobacter pylori.
    Satoh K; Kimura K; Takimoto T; Kihira K; Taniguchi Y; Saifuku K
    J Gastroenterol; 1996 Nov; 31 Suppl 9():53-5. PubMed ID: 8959520
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of Helicobacter pylori infection 2017.
    O'Connor A; Lamarque D; Gisbert JP; O'Morain C
    Helicobacter; 2017 Sep; 22 Suppl 1():. PubMed ID: 28891137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular approaches and modern clinical strategies for the management of Helicobacter pylori infection in Japan.
    Suzuki H; Nishizawa T; Tsugawa H; Hibi T
    Keio J Med; 2012; 61(4):109-19. PubMed ID: 23324305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Infections caused by Helicobacter pylori].
    Stock I; Wiedemann B
    Med Monatsschr Pharm; 1997 Jan; 20(1):2-8. PubMed ID: 9082155
    [No Abstract]   [Full Text] [Related]  

  • 49. [Cost-benefit analysis of conservative therapy of gastritis and peptic ulcer].
    Schütz E; Stolte M
    Leber Magen Darm; 1994 Jul; 24(4):147-9. PubMed ID: 7934607
    [No Abstract]   [Full Text] [Related]  

  • 50. Evolution of Helicobacter pylori therapy from a meta-analytical perspective.
    Gisbert JP; Pajares R; Pajares JM
    Helicobacter; 2007 Nov; 12 Suppl 2():50-8. PubMed ID: 17991177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Helicobacter pylori and peptic ulcer disease. Reexamining the therapeutic approach.
    Fedotin MS
    Postgrad Med; 1993 Sep; 94(3):38-40, 43-5. PubMed ID: 8361941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Is gastric acid secretion inhibition necessary for successful eradication of Helicobacter pylori?].
    Müller P; Simon B
    Fortschr Med; 1996 Aug; 114(22-23):275-6. PubMed ID: 8974962
    [No Abstract]   [Full Text] [Related]  

  • 53. Guidelines in the medical treatment of Helicobacter pylori infection.
    Dzieniszewski J; Jarosz M
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():143-54. PubMed ID: 17033112
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of Helicobacter pylori-positive peptic ulcer disease.
    Malfertheiner P
    Scand J Gastroenterol Suppl; 1996; 215():69. PubMed ID: 8722386
    [No Abstract]   [Full Text] [Related]  

  • 55. Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
    Demir M; Göktürk S; Oztürk NA; Serin E; Yilmaz U
    Digestion; 2010; 82(1):47-53. PubMed ID: 20410684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa--possible mechanism for cure of peptic ulcer disease and MALT lymphoma with a low-grade malignancy.
    Ohara T; Kanoh Y; Higuchi K; Arakawa T; Morisita T
    Hepatogastroenterology; 2003; 50(51):607-9. PubMed ID: 12828043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of Helicobacter pylori infection.
    Miehlke S; Bayerdörffer E; Graham DY
    Semin Gastrointest Dis; 2001 Jul; 12(3):167-79. PubMed ID: 11478749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Therapy of Helicobacter pylori infection].
    Treiber G
    Praxis (Bern 1994); 2000 May; 89(22):958-62. PubMed ID: 10893994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
    Ergül B; Doğan Z; Sarikaya M; Filik L
    Helicobacter; 2013 Dec; 18(6):454-8. PubMed ID: 24011287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.